Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:56:00 13/01/2026 GMT			5-day change	1st Jan Change
385.75 ^DKK	+1.75%		+11.09%	+18.43%

12:52pm	Global drugmakers rush to boost US presence as tariff threat looms	RE
10:41am	Danske Bank Lowers Price Target for Novo Nordisk to 455 Danish Kroner (from 480), Reiterates Buy - BN	FW

Novo Nordisk valuation hit by obesity fears

Novo Nordisk is facing heavy market pressure from obesity and Alzheimer’s headlines, US pricing agreements and tougher competition from Eli Lilly and compounders. Yet its leadership in obesity treatments, robust pipeline and resilient margins argue against writing the stock off.

Published on 11/25/2025 at 09:42 am GMT - Modified on 11/25/2025 at 09:09 am GMT

Alphavalue

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

12:52pm	Global drugmakers rush to boost US presence as tariff threat looms	RE
10:41am	Danske Bank Lowers Price Target for Novo Nordisk to 455 Danish Kroner (from 480), Reiterates Buy - BN	FW
08:16am	Novo Nordisk CEO Sees Wegovy Pills Helping the Company Expand in the US - BN	FW
07:13am	Focus on inflation and corporate earnings
12:41am	Amgen says MariTide helped trial patients maintain weight loss	RE
12:16am	Appetite for weight-loss deals broader than visible, Viking CEO says	RE
11:46pm	Amgen to announce data on obesity drug MariTide at healthcare conference	RE
11:42pm	Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra	RE
01-12	Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030	RE
01-12	Novo Nordisk sees pills capturing over third of GLP-1 market by 2030	RE
01-12	Novo EVP for Product and Portfolio Strategy Ludovic Helfgott: Market for Oral Weight-Loss Drugs Could Be One-Third Plus of Overall Market by Turn of Decade	RE
01-12	Novo Nordisk EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought	RE
01-12	Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs	RE
01-12	Doustdar: Compounders grabbed price-sensitive consumers of GLP1 and that is a learning for Novo	RE
01-12	Doustdar: Still fighting against compounded versions of Wegovy	RE
01-12	NOVO NORDISK : Gets a Buy rating from Berenberg	ZD
01-09	Health Care Up Amid Deal Speculation -- Health Care Roundup	DJ
01-09	Sector Update: Health Care Stocks Decline Late Afternoon	MT
01-09	Sector Update: Consumer Stocks Gain Late Afternoon	MT
01-09	Sector Update: Consumer	MT
01-09	Sector Update: Health Care Stocks Mixed Friday Afternoon	MT
01-09	Concentration, passive management and back-to-basics discipline: Terry Smith's read for 2025-2026
01-09	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals	MT
01-09	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026	RE
01-09	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

78,554

Sector

Pharmaceuticals

Calendar

02-04 - Q4 2025 Earnings Release

More about the company